You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


Takeda’s Exkivity receives MHRA conditional marketing authorisation

The Medicines and Healthcare products Regulatory Agency (MHRA) has granted a conditional marketing authorisation to Exkivity (mobocertinib), as a monotherapy treatment for adult patients with epidermal growth factor receptor (EGFR) locally advanced or metastatic non-small cell lung cancer.